Elsevier to Unveil “BrainNavigator” at ‘Neuroscience 2008’
Neuroscience Research Goes Digital with Online, 3D Mapping For Faster, More Accurate Research
Washington, D.C. November 14, 2008 – A revolutionary product that will change the face of brain research was announced today by Elsevier in partnership with the Allen Institute for Brain Science. BrainNavigator, a 3D research tool, will replace bulky desk atlases and move brain research online, saving scientists time while improving the quality of day-to-day research.
BrainNavigator is an electronic brain map that combines the coronal, transverse and sagittal atlases on easy-to-navigate planes that show detailed image descriptions of each brain section. Instead of printed graphs, BrainNavigator provides a 3D precise picture, allowing for better visualization, enhanced accuracy and increased productivity. Researchers are also able to slice the brain virtually and overlay images to see sections that previously took hours to link. The preciseness of measurements on BrainNavigator leads to faster and easier identification, marking, and visualization of brain structures for researchers who depend on accurate research data.
“We are delighted to combine our cutting-edge 3-D technology with Elsevier's leading brain atlases in order to create valuable open access resources as a part of BrainNavigator,” said Allan Jones, Ph.D., Chief Scientific Officer of the Allen Institute for Brain Science. “By providing meaningful tools and rich content to the research community in a mixture of free and subscription content, the Allen Institute for Brain Science and Elsevier enable important advancements in brain research worldwide with BrainNavigator.”
“BrainNavigator will change the way Neuroscience research is conducted,” said Dr. Johannes Menzel, Publisher for Science and Technology at Elsevier. “By creating a research platform on a digital front instead of massive desk atlases, scientists can more effectively work while actively comparing against existing information. This tool is revolutionary for brain science.”
Elsevier will demo the prototype at Neuroscience 2008 in Washington D.C. and begin registering potential beta testers. Scheduled for release in May 2009, registered users will have free access to select content on the BrainNavigator prior to purchase. A Webcast demonstration on November 14, along with on-site tutorials at the Neuroscience 2008 tradeshow in Washington D.C., will demonstrate to researchers how it will truly alter life in the lab.
About the Allen Institute for Brain Science
Launched in 2003, the Seattle-based Allen Institute for Brain Science is an independent, 501(c)(3) non-profit medical research organization dedicated to advancing brain research. Started with $100 million in seed money from philanthropist Paul G. Allen, the Institute takes on projects at the leading edge of science - far-reaching projects at the intersection of biology and technology. The resulting data create publicly available resources that fuel discovery for countless other researchers worldwide. The Institute’s data and tools are available on the Web free of charge at www.alleninstitute.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 212 752 8338